Protective effects of 1&#945;,25-Dihydroxyvitamin D3 on cultured neural cells exposed to catalytic iron by UBERTI, FRANCESCA et al.
ORIGINAL RESEARCH
Protective effects of 1a,25-Dihydroxyvitamin D3 on cultured
neural cells exposed to catalytic iron
Francesca Uberti* Vera Morsanuto* Claudio Bardelli & Claudio Molinari
Laboratory of Physiology, Department of Translational Medicine, UPO – University of Eastern Piedmont, Novara, Italy
Keywords
Active vitamin D, catalytic iron, human
neuronal cells.
Correspondence
Francesca Uberti, Department of Translational
Medicine, UPO – University of Eastern
Piedmont, via Solaroli 17, 28100 Novara,
Italy.
Tel: +390321660653
Fax: +390321620421
e-mail: francesca.uberti@med.uniupo.it
Funding Information
No funding information provided.
Received: 7 March 2016; Revised: 23 March
2016; Accepted: 25 March 2016
doi: 10.14814/phy2.12769
Physiol Rep, 4 (11), 2016, e12769, doi:
10.14814/phy2.12769
*These authors contributed equally to the
study and are co-first authors.
Abstract
Recent studies have postulated a role for vitamin D and its receptor on cere-
bral function, and anti-inflammatory, immunomodulatory and neuroprotec-
tive effects have been described; vitamin D can inhibit proinflammatory
cytokines and nitric oxide synthesis during various neurodegenerative insults,
and may be considered as a potential drug for the treatment of these disor-
ders. In addition, iron is crucial for neuronal development and neurotransmit-
ter production in the brain, but its accumulation as catalytic form (Fe3+)
impairs brain function and causes the dysregulation of iron metabolism lead-
ing to tissue damage due to the formation of toxic free radicals (ROS). This
research was planned to study the role of vitamin D to prevent iron damage
in neuroblastoma BE(2)M17 cells. Mechanisms involved in neurodegeneration,
including cell viability, ROS production, and the most common intracellular
pathways were studied. Pretreatment with calcitriol (the active form of vita-
min D) reduced cellular injury induced by exposure to catalytic iron.
Introduction
Vitamin D, particularly its active form (calcitriol, 1al-
pha,25-dihydroxyvitamin D3), is known for its role in cal-
cium and bone homeostasis, cell proliferation, and
modulation of parathyroid hormone secretion (Honmou
et al. 2012). Recently, a number of extraskeletal actions of
vitamin D have been reported, including effects on nitric
oxide production, antioxidant activity, and endothelial
proliferation and migration (Molinari et al. 2011; Uberti
et al. 2014; Pittarella et al. 2015). Vitamin D acts on cells
and tissues that express a nuclear receptor called VDR.
Although in human, most of the vitamin D that ends up in
the blood is produced in the kidneys, vitamin D may be
synthesized in other tissues such as endothelium, placenta,
prostate, skin, colon, breast, and the central nervous system
(CNS). The production of vitamin D by these tissues/or-
gans is low compared to the amount produced by kidneys,
and this vitamin D is probably not released back into the
blood but acts within the tissue where it is made (Garcion
et al. 2002; Tetich et al. 2004; Cranney et al. 2007). As
regards the CNS, several recent studies have postulated
anti-inflammatory, immunomodulatory, and neuroprotec-
tive roles for vitamin D (Garcion et al. 2002). Both 1alpha-
hydroxylase and VDR are widely expressed in neurons and
glial cells, suggesting that vitamin D may have autocrine
and paracrine actions in the brain (Pr€ufer et al. 1999; Eyles
et al. 2005). VDR is expressed in several regions (Tetich
et al. 2004) of animal (Garcion et al. 2002) and human
(Kalueff et al. 2006) brains, particularly in the pontine-
midbrain area, cerebellum, thalamus, hypothalamus, basal
ganglia, hippocampus, olfactory system and temporal,
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orbital and cingulate areas of the cortex (Eyles et al. 2003).
Mounting evidence indicates that vitamin D and its
receptor have effects that include neuroprotection and
immunomodulation (Aloia et al. 2010). Moreover, vitamin
D is a regulator of brain cell proliferation and differentia-
tion, and has an essential role in the brain development
(Chopp et al. 2007; Stewart et al. 2010) and neurotrans-
mitter synthesis (Tetich et al. 2004). Vitamin D can exert
these effects due to its ability to cross the blood–brain bar-
rier and to bind to VDR within the brain (Chowdhury
et al. 2012; Kienreich et al. 2013). Upon binding, VDR
forms a complex with a retinoid X receptor that controls
gene expression (Arbelle et al. 1996; Thompson et al.
1998). Gestational vitamin D deficiency induces long-last-
ing alterations in the brain structure, including changes in
volume, cell proliferation and reduced expression of nerve
growth factors, glia-derived neurotrophic factor, and neu-
rotrophins 3 and 4 (Eyles et al. 2003; Tetich et al. 2004;
Cui et al. 2007). Moreover, vitamin D can protect neurons
against NMDA, glutamate, 6-hydroxydopamine, and reac-
tive oxygen species (Brewer et al. 2001; Ibi et al. 2001). It
has been hypothesized that vitamin D exerts these effects
by modulation of neuronal Ca2+ homeostasis, in particular
through downregulation of L-type voltage-sensitive Ca2+
channels in hippocampal neurons against excitotoxic
insults (Tetich et al. 2005), accompanied by an increase in
VDR density. Vitamin D can inhibit proinflammatory
cytokine and nitric oxide synthesis (Garcion et al. 1997)
induced during various insults or disorders, such as ische-
mia and reperfusion, Alzheimer’s disease, Parkinson’s dis-
ease, AIDS, infection, multiple sclerosis, and experimental
autoimmune encephalomyelitis. For these reasons, it may
be considered as a potential treatment of neurodegenera-
tive disorders.
Early vitamin D deficiency may be a risk factor for a
number of disorders including schizophrenia, autism
(Thompson et al. 1998; Pilz et al. 2011; Chowdhury et al.
2012), multiple sclerosis, Parkinson’s disease, and stroke
(Sun et al. 2012). Several neurodegenerative disorders
have been associated with the dysregulation of iron meta-
bolism (Ponka 2004) including Huntington’s disease,
Parkinson’s disease, and neurodegeneration with iron
accumulation (Mena et al. 2015). Iron is involved in a
wide range of cellular processes, including DNA synthesis
and repair, energy metabolism, phospholipids metabo-
lism, and oxidative phosphorylation (Salvador 2010; Park
et al. 2015). In addition, iron is crucial for neuronal
development and neurotransmitter production in the
brain (Sipe et al. 2002; Park et al. 2015). However, the
accumulation of iron as catalytic form (Fe3+) impairs the
brain function, and dysregulation of iron metabolism
results in tissue damage due to the formation of toxic free
radicals (ROS) (Lipinski 2011; Urrutia et al. 2014; Park
et al. 2015). Neurons have highly regulated mechanisms
for controlling cellular iron levels. The uptake is con-
trolled by transferrin receptor-1 or by divalent metal
transporter-1 (DMT1; Moos et al. 2007; Dev et al. 2015).
The uptaken iron is stored within ferritin to avoid iron-
mediated damage and preserved for other cellular activi-
ties (Hentze and Kuhn 1996; Rouault and Cooperman
2006; Andrews and Schmidt 2007; Dev et al. 2015). Cells
also control iron levels by releasing it through ferroportin
(Abboud and Haile 2000; Hentze et al. 2004; Dev et al.
2015). Inappropriate regulation of one of these mecha-
nisms may result in accumulation of iron. Neurons can-
not reduce intracellular iron by cell division, so iron
concentration control depends on cellular iron homeosta-
sis. Although iron content increases with age (Zecca et al.
2001; Gotz et al. 2004; Mura et al. 2006), a large portion
of neuronal cells stay viable and control the degree of
oxidative damage, presumably through the activation of
adaptive mechanisms (Mura et al. 2006).
Neuronal iron accumulation is thought to be involved
in several neurodegenerative disorders, but the molecular
events underlying the toxicity remain unknown. Recently,
a relationship between iron and vitamin D has been
observed, especially in the context of iron deficiency and
anemia (Lee et al. 2009). Moreover, a neuroprotective
effect of vitamin D against iron-induced oxidative injury
in locus coeruleus of rat has been reported (Chen et al.
2003).
However, little is known about its role in counteracting
the harmful effects of intraneuronal iron accumulation.
The present research was planned to study the effects
of vitamin D on iron accumulation after 6 days of stimu-
lation in BE(2)M17 neuroblastoma cells. (Filograna et al.
2015). Mechanisms involved in neurodegeneration, such
as cell viability, ROS production, and the most common
intracellular pathways were studied.
Material and Methods
Cell culture
Human neuroblastoma BE(2)-M17 cells were cultured as
previously described (Filograna et al. 2015) in a 1:1 mix-
ture of Ham’s F12 and Dulbecco’s Modified Eagle’s Med-
ium (Sigma-Aldrich, Milan) supplemented with 10% fetal
bovine serum (FBS, Sigma-Aldrich, Milan), 1% penicillin/
Streptomycin (Sigma-Aldrich, Milan), and grown in the
presence of 5% CO2 in an incubator at 37°C. In all experi-
ments, cells were used at early passages (P1-5 after pur-
chase from LGC standards). To study cell viability (MTT
test) and ROS production, 1 9 104 cells were plated on
96-well plates; to perform iron staining (Perl’s and Turn-
bull), immunocytochemistry and immunofluorescence
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studies, 0.25 9 104 cells were placed in CultureSlide (BD,
Bedford, MA) with four chambers; to analyze the intracel-
lular pathways through western blot analysis, cells were
plated on 60-mm culture dishes until confluence.
Experimental protocol
BE(2)M17 cells were treated with different concentrations
of catalytic iron (Fe3+) in a range (from 75 to 300 lmol/
L) that was able to induce neurodegeneration (Park et al.
2015). The same stimulations were replicated after pre-
treatment with calcitriol in a range (0.1–100 nmol/L)
reported in literature (Bini et al. 2012) as causing no sig-
nificant change in cell viability. Before stimulation, cells
were synchronized overnight in serum-free medium and
incubated in the culture medium without red-phenol sup-
plemented with 5% FBS, 1% penicillin/streptomycin,
before and during treatment. Stimulation with 1 nM cal-
citriol was maintained for 6 days and replicated as pre-
treatment for 6 days before stimulation with catalytic iron
for another 6 days.
Iron staining
Perls’ stain was used to visualize, respectively, ferric iron
(Fe3+) and ferrous iron (Fe2+) in BE(2)M17 cells as
reported in the literature (Meguro et al. 2007; Dang et al.
2011; Owen et al. 2015). Cells cultured in chamber slide,
as described before, were washed three times with cold
PBS 19 supplemented with 2 mmol/L sodium orthovana-
date, and fixed using a cold fixative solution (3.7%
formaldehyde, 3% sucrose in PBS 19) for 20 min at RT.
Slides to be stained for Fe3+ were incubated with potas-
sium ferrocyanide, then with potassium ferrocyanide +
HCl, for 30 min each (Perls’ method). Finally, they were
counterstained with safranin-O and mounted with Bio
Mount (Bio-Otika, Milan, Italy). The intensity of Perls’
staining was semiquantified from five photomicrographs
per chamber (Owen et al. 2015). All micrographs were
taken at the same magnification. Luminosity signals were
determined using ImagePro 3 software (NIH, Bethesda,
US), and the results were expressed as means  SD (%).
MTT test
MTT dye (Sigma-Aldrich) was used to determine cell via-
bility. After stimulation, cells were incubated with 1%
MTT dye for 2 h at 37°C in an incubator as previously
described (Uberti et al. 2014; Lattuada et al. 2015). The
purple formazan crystals (3-[4,5-dimethylthiazol-2-y1]-
2,5- diphenyltetrazoliumbromide) were dissolved in
DMSO. Cell viability was determined by measuring the
absorbance through a spectrometer (VICTORX3
Multilabel Plate Reader) at 570 nm with correction at
690 nm, and cell viability calculated by comparing results
to control cells (100% viable).
ROS production
The rate of superoxide anion release was used to examine
the effects of calcitriol against the oxidative stress induced
by catalytic iron. Superoxide anion production was mea-
sured as superoxide dismutase-inhibitable reduction of
cytochrome C, as previously described (Uberti et al. 2014).
In all samples (both stimulated and untreated), 100 lL of
cytochrome C was added, and in one group, 100 lL of
superoxide dismutase was also added for 30 min in the
incubator (all substances from Sigma-Aldrich). The absor-
bance changes in the sample supernatants were measured
at 550 nm in a spectrometer (VICTORX3 Multilabel
Plate Reader). O2 was expressed as nanomoles per reduced
cytochrome C per microgram of protein, using an extinc-
tion coefficient of 21,000 mL/cm, after interference absor-
bance subtraction (Lattuada et al. 2015).
Western Blot for ferritin, VDR, p53, c-Myc,
Ki67, and ERK1/2/MAPK
Cells were washed and then lysed in ice with Complete
Tablet buffer (Roche) supplemented with 2 mmol/L
sodium orthovanadate, and 1:1000 phenylmethanesul-
fonylfluoride (PMSF; Sigma-Aldrich). A quantity of 35 lg
of protein from each lysate was loaded on 15 or 5% SDS-
PAGE gels and transferred to polyvinylidene fluoride
membranes (PVDF, GE Healthcare Europe GmbH, Milan,
Italy). They were incubated overnight at 4°C with specific
primary antibody: anti-ferritin (1:250, Santa-Cruz), anti-
VDR (D-6) (1:200, Santa-Cruz), anti-p53 (1:500, Santa-
Cruz), anti-cMyc (1:200, Millipore S.p.A., Milan, Italy),
anti-Ki67 (1:500, Santa-Cruz), anti-Phospho-p44/42
MAPK (Thr202/Tyr204, 1:1000 Cell-Signaling). Protein
expression was normalized and verified through ß-actin
detection (1:5000; Sigma, Milan, Italy).
c-Myc, Ki67 immunocytochemistry
Cells, fixed as described above, were washed twice with
cold PBS 1X, permeabilized with cold PBS 19 with cold
0.5% Triton X-100 on ice at 4°C for 20 min and washed
with PBS 19. Then, the chamber slides were incubated
with 3% hydrogen peroxide in PBS 19 for 8 min to
block endogenous peroxidase activity and maintained in a
blocking solution composed of PBS 19 with 3% albumin
from bovine serum (BSA, Sigma, Milan, Italy) for 1 h at
room temperature. The slides were incubated overnight at
4°C with specific primary antibody: 1:50 c-Myc, 1:50
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Ki67. All antibodies were diluted in PBS 19 in a humidi-
fied chamber and then incubated for 20 min with diluted
biotinylated secondary antibody solution (Dako Italia,
Milan, Italy) and then for 20 min with VECTASTAIN
ABC Reagent (Dako Italia, Milan, Italy). Finally, sections
were washed, incubated with peroxidase substrate solution
until the desired stain intensity had developed (Peroxi-
dase/DAB, Dako Italia, Milan, Italy), rinsed in tap water,
counterstained with Mayer’s hematoxylin, and mounted
with Bio Mount (Bio-Optica, Milan, Italy). The number
of positive cells was calculated as described elsewhere (Lee
et al. 2009); briefly, 12 different areas (1 mm2) randomly
selected from each section were taken, and the number of
signals was determined using ImagePro 3 software (NIH,
Bethesda, US). The results were expressed as a
means  SD (%).
p53 immunofluorescence
Cells, fixed as described above, were washed with cold PBS
1X, permeabilized with cold PBS 19 with 0.5% Triton X-
100 for 20 min at 4°C, incubated in blocking solution (1%
BSA and 5% FBS in PBS 1X) for 30 min at RT and then
treated with p53 specific antibody (1:50, Santa- Cruz) in
PBS 19 overnight at 4°C. The slides were then incubated
with fitch-secondary antibodies (1:200, Sigma-Aldrich) in
PBS 19 for 1 h in the dark, counterstained with DAPI
(1 lg/mL; Sigma- Aldrich) diluted in PBS 19 for 5 min in
the dark at room temperature and finally mounted in Vec-
tashield (D.B.A. Italia). The number of positive cells was
calculated as described by Lee et al. (2009): briefly, 12 dif-
ferent areas (1 mm2) randomly selected from each section
were taken, and the number of signals was determined
using ImagePro 3 software (NIH, Bethesda, US). The
results were expressed as means  SD (%).
Statistical analysis
For each experimental protocol, at least four independent
experiments were run; the results are expressed as
means  SD of four technical replicates. One-way
ANOVA followed by Bonferroni post hoc test was used
for statistical analysis, and pairwise differences compared
by Mann-Whitney U tests. P-values <0.05 were consid-
ered statistically significant.
Results
Cell viability and reactive oxygen species
(ROS) production in neuroblastoma cells
The effect of calcitriol was analyzed by the stimulation of
BE(2)M17 cultures with different doses (from 0.01 to
Figure 1. Effects of calcitriol (cal) on cell viability and ROS
production. (A) dose–response study of vitamin D (0.01–100 nmol/
L) on viability of BE(2)M17 cells. cal = calcitriol; ET-OH = ethanol.
*P < 0.05 versus control. (B) MTT test in cells treated with catalytic
iron (75–300 lmol/L) alone for 6 days or pretreated with 1 nmol/L
calcitriol for 6 days. a, b, c, e, f versus control (0%); b, c, e
P < 0.05 versus a; a, c, f P < 0.05 versus b; a, b, c P < 0.05 versus
c; e, f, g P < 0.05 versus d; e, f P < 0.05 versus g. (C) ROS
production (expressed as cytochrome C reduced per lg of protein)
in cells treated with catalytic iron (75–300 lmol/L) alone for 6 days
or pretreated with 1 nmol/L calcitriol for 6 days. b, c, d, e, g
P < 0.05 versus a; g, h P < 0.05 versus f; g P < 0.05 versus h; c, d
P < 0.05 versus e; c P < 0.05 versus d. In both panels, results are
expressed as means  SD (%) of four technical replicates
normalized to control values.
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100 nmol/L, dissolved in ethanol) measuring cell viability
through MTT test after 6 days. As illustrated in a dose–
response study (Fig. 1A), after 6 days, the effect of cal-
citriol was concentration-dependent, with a minimally
effective dose of 1 nmol/L (0.17  1.89% vs. control).
This concentration was used for all successive experi-
ments. The effect of the solvent of calcitriol was also
tested.
The influence of calcitriol on the effects of Fe3+ on the
viability of BE(2)M17 cells was studied. As shown in Fig-
ure 1B, catalytic iron alone decreased cell viability in a
concentration and time-dependent manner, confirming
data reported previously (Park et al. 2015). A maximal
reduction was observed in the presence of 300 lmol/L
Fe3+ (31.5  3.9% vs. control, P < 0.05). Pretreatment
with calcitriol counteracted the decrease on cell viability
induced by catalytic iron in a dose-dependent manner
and the maximum effect, of about 90% was observed in
the presence of 300 lmol/L calcitriol (P < 0.05 vs. cat-
alytic iron alone).
The same conditions were reproduced to analyze ROS
production in BE(2)M17 cells (Fig. 1C). In cells treated
with calcitriol alone, no significant release of ROS into
the cell medium was observed demonstrating that the
treatment did not lead to cell death. On the contrary, in
cells treated with catalytic iron alone, there was a signifi-
cant dose-dependent increase in ROS production
Figure 2. Perl’s staining to visualize ferric iron accumulation after pretreatment for 6 days with 1 nmol/L calcitriol (cal) and treatment with Fe3+
(from 75 to 300 lmol/L) for 6 days on BE(2)M17 cells. Representative pictures reported were an example of four technical replicates taken by
microscopy at original magnification 940. The scale bar (50 lmol/L) in the first image is valid for all pictures. The ratio reported is a mean
(SD) (%) of positive cells counted in 12 different areas. b, c, d, f, g, h P < 0.05 versus a; c, d, f P < 0.05 versus b; h P < 0.05 versus d; f, g, h
P < 0.05 versus e; f, g P < 0.05 versus h; g P < 0.05 versus h.
Figure 3. Ferritin studies by western blot and densitometric analysis
after pretreatment of BE(2)M17 cells for 6 days with 1 nmol/L calcitriol
(cal) and treatment with Fe3+ (from 75 to 300 lmol/L) for 6 days.
Protein extracts were analyzed by immunoblotting with specific
antibodies against the indicated proteins; results are expressed as
means  SD (%) normalized to control values of four technical
replicates; b, c, d, f, g, h P < 0.05 versus a; f P < 0.05 versus b; d, g
P < 0.05 versus c; f, g, h P < 0.05 versus e; g P < 0.05 versus f.
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(Fig. 1C, P < 0.05). The maximum effect was obtained by
300 lmol/L (114.6  1.84 of cytochrome C reduced per
lg of protein). Pretreatment with calcitriol was able to
counteract the ROS production induced by catalytic iron
and this effect was more evident in the presence of
150 lmol/L calcitriol (21.1  2.5 cytochrome C reduced
per lg of protein; P < 0.05) and 300 lmol/L Fe3+
(13.6  2.8 cytochrome C reduced per lg of protein;
P < 0.05) compared to catalytic iron alone (47.4  1.86
and 114.6  1.84 cytochrome C reduced per lg of pro-
tein, respectively; P < 0.05). These data demonstrate the
ability of calcitriol to prevent the negative effects of
oxidative stress caused by catalytic iron on neural cells.
Analysis of iron accumulation after 6 days
of treatment with catalytic iron
Perls’s stain for ferric iron (catalytic) was used to study
the involvement of vitamin D in preventing iron
accumulation. Calcitriol alone did not influence Perls’s
stain compared to control (P > 0.05; Fig. 2). On the con-
trary, in neuroblastoma cells treated with different con-
centrations of catalytic iron, a dose-dependent
accumulation of Fe3+ was observed. The maximum effect
was observed in the presence of 300 lmol/L Fe3+ and the
highest concentration was observed in the perinuclear
regions of living cells. Pretreatment with calcitriol was
able to modulate this accumulation. Indeed, the number
of positive cells significantly decreased (of about 65%;
P < 0.05) compared to catalytic iron treatment alone.
To confirm these data, ferritin, a protein involved in
iron storage, was measured by western blot (Fig. 3). Fer-
ritin, the main iron storage protein in mammalian cells,
is considered to be the first line of defense against iron
overload. Exposure to increasing concentrations of cat-
alytic iron from 75 to 300 lmol/L caused a significant
increase in cell ferritin content (Fig. 3). At 300 lmol/L
extracellular Fe3+, ferritin showed a tripled increase
Figure 4. Western blot and densitometric analysis after pretreatment of BE(2)M17 cells for 6 days with 1 nmol/L calcitriol (cal) and treatment
with catalytic iron (75–300 lmol/L) for 6 days. Results are expressed as means  SD (%) normalized to control values of four technical
replicates. (A) shows western blot of protein extracts analyzed by immunoblotting with a specific antibody against VDR and densitometric
analysis of VDR. d, e, f, g, h P < 0.05 versus a; f P < 0.05 versus b; g P < 0.05 versus e; f, h P < 0.05 versus g; h P < 0.05 versus d; g P < 0.05
versus c. (B) shows western blot of protein extracts analyzed by immunoblotting with a specific antibody against p-ERK and densitometric
analysis of p-ERK. b, c, d, e, d, f, g, h P < 0.05 versus a; c, d, f P < 0.05 versus b; d, g, P < 0.05 versus c; g, h P < 0.05 versus e; g, h P < 0.05
versus f; h P < 0.05 versus g; h P < 0.05 versus d.
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Figure 5. Western blot and densitometric analysis after pretreatment of BE(2)M17 cells for 6 days with 1 nmol/L calcitriol (cal) and treatment
with catalytic iron (75–300 lmol/L) for 6 days. The results are expressed as means  SD (%) normalized to control values of four technical
replicates (A) shows western blot of protein extracts analyzed by immunoblotting with a specific antibody against p53 and densitometric
analysis of p53. b, c, d, f, h P < 0.05 versus a; c, d, f P < 0.05 versus b; d, g P < 0.05 versus c; h P < 0.05 versus d; f, g, h P < 0.05 versus e;
g, h P < 0.05 versus f; h P < 0.05 versus g. (B) shows western blot of protein extracts analyzed by immunoblotting with a specific antibody
against ki67 and densitometric analysis of ki67. b, c, d, f, g, h P < 0.05 versus a; f, g, h P < 0.05 versus e; c, d, f P < 0.05 versus b; d, g
P < 0.05 versus c; h P < 0.05 versus d; g, h P < 0.05 versus f; h P < 0.05 versus g. (C) shows western blot of protein extracts analyzed by
immunoblotting with a specific antibody against c-Myc and densitometric analysis of c-Myc. b, c, d P < 0.05 versus a; c, d, f P < 0.05 versus b;
d, g P < 0.05 versus c; h P < 0.05 versus d; f P < 0.05 versus e.
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(P < 0.05 vs. control). On a molar basis, ferritin pro-
duced a greater increase than catalytic iron. Pretreatment
with calcitriol prevented this increase in ferritin expres-
sion: at 300 lmol/L, ferritin doubled (P < 0.05) com-
pared to control. These data confirmed the observations
described in Figure 2 on the protective effects of calcitriol
against damage depending on iron accumulation.
Study of the intracellular pathways
activated by calcitriol
The presence of VDR receptors in neuroblastoma cells
was studied by western blot and densitometric analysis
(Fig. 4A). The protein expression was augmented com-
pared to control (about 50%, P < 0.05) in the presence
of calcitriol alone, demonstrating that calcitriol may
exert its effects by VDR receptor signaling. The samples
treated with Fe3+ did not induce a significant change in
VDR expression, but in samples pretreated with cal-
citriol, an increase in VDR expression was observed
compared to control, indicating the possible involvement
of VDR in the protective effects exerted by calcitriol. In
this context, the role of MAPK, a marker of cell prolif-
eration, was examined. In samples treated with calcitriol
alone, the activation of ERK was similar to control, con-
firming data obtained from MTT test on the ineffective
dose of calcitriol (Fig. 4B). In samples treated with cat-
alytic iron alone, the activation of ERK was overex-
pressed in a dose-dependent manner, suggesting that
iron-dependent generation of ROS activates the ERK/
MAPK pathway. On the other hand, pretreatment with
calcitriol attenuated the overexpression caused by cat-
alytic iron (P < 0.05).
Analysis of the neurodegenerative markers:
p-53, Ki67, c-myc
p53, Ki67, and c-Myc expressions were investigated by
western blot and densitometric analysis in BE(2)M17 cells
treated with the same agents and under the same condi-
tions as previously reported. Calcitriol alone had no sig-
nificant effect on these markers (Fig. 5). In the presence
of catalytic iron, dose-dependent activations p53, Ki67,
and c-Myc were observed (Fig. 5), and maximum effects
were observed with 300 lmol/L Fe3+ after 6 days of
treatment (3, 10, and 1.5 fold activation, respectively, vs.
control values). Similar data were observed in
immunofluorescence (p53) and immunocytochemistry
experiments (Ki67, c-Myc; Fig. 6). Pretreatment with cal-
citriol for 6 days counteracted the iron-induced activation
of p53, Ki67, and c-Myc (Figs 5 and 6). These effects
were more evident in samples treated with 300 lmol/L
Fe3+ (0.9, 1, and 0 fold of activation, respectively).
Figure 6. Analysis of positivity of cells by immunofluorescence and
immunocytochemistry in BE(2)M17 cells pretreated for 6 days with
1 nmol/L calcitriol (cal) and treated with catalytic iron (75–
300 lmol/L) for 6 days. Data are expressed as means (SD) of
positive cells counted in 12 different areas in percentage obtained
by four technical replicates. (A) shows p53 positive cells. b, c, d, f,
g, h P < 0.05 versus a; c, d, f P < 0.05 versus b; d, g P < 0.05
versus c; h P < 0.05 versus d; f, g, h P < 0.05 versus e; g, h
P < 0.05 versus f; h P < 0.05 versus g. (B) shows the ratio of ki67
positive cells. b, c, d, e, f, g, h P < 0.05 versus a; f P < 0.05 versus
b; g P < 0.05 versus c; h P < 0.05 versus d; f, g, h P < 0.05 versus
e; g, h P < 0.05 versus f; h P < 0.05 versus g. (C) shows the ratio
of c-Myc positive cells. b, c, d, f, g, h P < 0.05 versus a; c, d, f,
P < 0.05 versus b; g P < 0.05 versus c; h P < 0.05 versus d; f, g
P < 0.05 versus e; g, h P < 0.05 versus f.
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Discussion
Although iron is an essential element, its intraneuronal
accumulation can be toxic due to its capability of switch-
ing between ferrous and ferric states. The latter impairs
iron metabolism, leading to neurodegenerative disorders
including Alzheimer’s and Parkinson’s diseases (Smith
et al. 1997; Takanashi et al. 2001).
As regards the mechanism of iron-induced neuronal
damage, it has been hypothesized that iron acquired by
neurons accumulates in mitochondria. Neuronal death is
preceded by the change in the mitochondria morphol-
ogy, from a continuous to a fragmented profile, and by
the loss of the mitochondrial membrane potential
(Pelizzoni et al. 2011; Park et al. 2015). Another impor-
tant factor implicated in mitochondrial fragmentation is
the oxidative stress, also associated with several neurode-
generative disorders (Urrutia et al. 2013; Singh et al.
2014; Dev et al. 2015). Iron-associated oxidative stress is
due to its participation in the Fenton reaction, which
generates ROS and consequently induces irreversible
damage to DNA, RNA, proteins, and lipids (Urrutia
et al. 2014). In this context, a relationship between iron,
oxidative stress, and neuronal loss has been established
(Gao et al. 2009; Salvador and Oteiza 2011). To reduce
iron damage in the brain, Chen et al. (2003) first sug-
gested a possible use of vitamin D supplementation,
after reporting that systemic administration of vitamin
D attenuates iron-induced oxidative injuries in the rat
locus coeruleus. Thus, there is evidence that the neuro-
protective action of vitamin D involves neuronal
calcium regulation, antioxidative pathway, immunomod-
ulation, and detoxification.
This study demonstrates that calcitriol can prevent
Fe3+-dependent oxidative injury in a neuronal cell line.
The beneficial effect consists in decrease in iron accu-
mulation and ROS production, two co-factors of neu-
rodegeneration (Cantu et al. 2009). In addition, the
observed effects of calcitriol in BE(2)M17 cells involved
the activation of VDR receptor. Moreover, under our
conditions, the survival pathway (ERKs) in the pres-
ence of calcitriol was also activated. In addition, Fe3+-
dependent activation of the neurodegenerative
biomarkers p53 (Herold et al. 2015), Ki67 (Wharton
et al. 2005) and c-Myc (Sleiman et al. 2011), was
confirmed.
In conclusion, the results described in this work high-
light that calcitriol can protect cultured BE(2)M17 cells
against Fe3+-related oxidative stress and iron accumulation.
The results support the potential use of vitamin D supple-
mentation as a therapeutic strategy in neurodegeneration
disorders.
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